Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23435952 | 1.00 | CHRM2 (0.41) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL23315373 | 1.00 | CHRM2 (0.41) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL9696811 | 0.92 | CHRM1 (0.40) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL25606145 | 0.92 | CHRM1 (0.40) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL7328671 | 0.84 | ALDH1A1 (0.40) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL12614403 | 0.83 | CHRM2 (0.43) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL7323607 | 0.81 | ALDH1A1 (0.42) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL25082064 | 0.80 | CHRM2 (0.41) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL12506844 | 0.77 | CHRM2 (0.47) | CHRM2KMT2AMEN1CYP2D6CHRM1 | |
| SCHEMBL25607288 | 0.77 | CHRM2 (0.47) | CHRM2KMT2AMEN1CYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023021149-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2023-02-23 | — | — | WO | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950477-A | Modulators of progranulin and methods of use thereof | 阿库达医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3724188-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20180051018-A1 | QUINUCLIDINE DERIVATIVE | LTT BIO-PHARMA CO., LTD. (JP) | 2018-02-22 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-0625979-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993015073-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-5091397-A | Cognition activators | BEECHAM GROUP P.L.C. (GB) | 1992-02-25 | — | — | US | disclosed |
| EP-0363085-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | CHRM2 4157/4885KMT2A 4519/4885MEN1 1138/4885 |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | CHRM2 4042/4885KMT2A 4546/4885MEN1 968/4885 |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | CHRM2 3/4885KMT2A 496/4885MEN1 4138/4885 |
| US-20180051018-A1 | QUINUCLIDINE DERIVATIVE | CHRM3, CHRM1, NQO2 | CHRM2 6/4885KMT2A 1774/4885MEN1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.